Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels

Clinical Toxicology

Volumn 52, Issue 10, 2014, Pages 1292-1295

  Al Abri, Suad ^a   Meier, Kathryn H ^a   Colby, Jennifer M ^b   Smollin, Craig G ^a,c   Benowitz, Neal L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Cardiogenic shock; Designer drugs; Fluroamphetamine; Laboratory analysis; Reverse takotsubo cardiomyopathy

Indexed keywords

ADRENALIN; AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; COTININE; DOBUTAMINE; DOPAMINE; FLUOXETINE; FUROSEMIDE; LISINOPRIL; MILRINONE; NALTREXONE; NAPROXEN; ONDANSETRON; SALBUTAMOL; SODIUM CHLORIDE; SPIRONOLACTONE; TRAZODONE; 4-FLUOROAMPHETAMINE; BIOLOGICAL MARKER; STREET DRUG;

ADULT; ARTICLE; ASSISTED VENTILATION; BLOOD LEVEL; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CASE REPORT; CHEST TIGHTNESS; DYSPNEA; ECHOCARDIOGRAPHY; EMERGENCY WARD; HEART EJECTION FRACTION; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOKINESIA; HYPOTENSION; INOTROPISM; INTRAAORTIC BALLOON PUMP; ISCHEMIA; LUNG EDEMA; MALE; MENTAL HEALTH; MYOCARDITIS; NEBULIZATION; OPIATE ADDICTION; SINUS TACHYCARDIA; TAKOTSUBO CARDIOMYOPATHY; URINE LEVEL; VOMITING; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG ABUSE; ELECTROCARDIOGRAPHY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SHOCK, CARDIOGENIC; TREATMENT OUTCOME;

ADOLESCENT; AMPHETAMINE-RELATED DISORDERS; AMPHETAMINES; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTROCARDIOGRAPHY; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; SHOCK, CARDIOGENIC; STREET DRUGS; TREATMENT OUTCOME;

EID: 84920046073     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2014.974262     Document Type: Article

References (25)

1. Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE. Psychostim-ulant-like effects of p-fluoroamphetamine in the rat. Eur J Pharmacol 1995; 287:105-113.
2. McElroy JF, Miller JM, Meyer JS. Fenfluramine, p-chloroamphet-amine and p-fluoroamphetamine stimulation of pituitary-adrenocor-tical activity in rat: evidence for differences in site and mechanism of action. J Pharmacol Exp Ther 1984; 228:593-599.
3. Fuller RW, Baker JC, Perry KW, Molloy BB. Comparison of 4-chloro-, 4-bromoand 4-fluoroamphetamine in rats: drug levels in brain and effects on brain serotonin metabolism, Neuropharmacology 1975; 14:739-746.
4. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007; 559:132-137.
5. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 2011; 337:218-225.
6. Europol drugs newsletter 2009.Alert 2009-001, Project SYNERGY, 4-fluoroamphetamine (EDOCF403292) 1. July 1-9.
7. United Nations Office on Drugs and Crime, Details for Phenethylam-ines, UNODC.org website ©2014 UNODC: https://www.unodc.org/LSS/SubstanceGroup/Details/275dd468-75a3-4609-9e96-cc5a2f0-da467 (Last access April 10 2014).
8. Brunt TM, Koeter MW, Niesink RJ, van den Brink W. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl) 2012; 220:751-762.
9. Rust KY, Baumgartner MR, Dally AM, Kraemer T. Prevalence of new psychoactive substances: a retrospective study in hair. Drug Test Anal 2012; 4:402-408.
10. Chen JP. Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J Invasive Cardiol 2007; 19:E89-E92.
11. Yeo KK, Wijetunga M, Ito H, Efrd JT, Tay K, Seto TB, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med 2007; 120:165-171.
12. Hung MJ, Kuo LT, Cherng WJ. Amphetamine-related acute myocar-dial infarction due to coronary artery spasm. Int J Clin Pract 2003; 57:62-64.
13. Kaye S, McKetin R, Dufou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007; 102:1204-1211.
14. Dande AS, Fisher LI, Warshofsky MK. Inverted takotsubo cardiomyo-pathy. J Invasive Cardiol 2011; 23:E76-E78.
15. Movahed MR, Mostafzi K. Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use. Echocardiography 2008; 25:429-432.
16. Subramaniam A, Cooke JC, Ernest D. "Inverted" tako-tsubo cardio-myopathy due to exogenous catecholamines. Crit Care Resusc 2010; 12:104-108.
17. Srikanth S, Barua R, Ambrose J. Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy. Cardiology 2008; 109:188-192.
18. Saiful FB, Lafferty J, Jun CH, Teli S, Duvvuri S, Khattri S, Bhat T. Takotsubo cardiomyopathy due to iatrogenic methadone withdrawal. Rev Cardiovasc Med 2011; 12:164-167.
19. Spadotto V, Zorzi A, Elmaghawry M, Meggiolaro M, Pittoni GM. Heart failure due to'stress cardiomyopathy': a severe manifestation of the opioid withdrawal syndrome. Eur Heart J Acute Cardiovasc Care 2013; 2:84-87.
20. Ò Vivitrol package information. http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/021897s005s010lbl. pdf. Accessed July 2014.
21. Röhrich J, Becker J, Kaufmann T, Zörntlein S, Urban R. Detection of the synthetic drug 4-fluoroamphetamine (4-FA) in serum and urine. Forensic Sci Int 2012; 215:3-7.
22. Johansen SS, Hansen TM. Isomers of fluoroamphetamines detected in forensic cases in Denmark. Int J Legal Med 2012; 126: 541-547.
23. Huang KL, Shaw KP, Wang D, Hsu K, Huang TS, Chen HI. Free radicals mediate amphetamine-induced acute pulmonary edema in isolated rat lung. Life Sci 2002; 71:1237-1244.
24. MenonV, Lessard D, Yarzebski J, Furman MI, Gore JM, Goldberg RJ. Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol 2003; 92:368-372.
25. Sutter ME, Gaedigk A, Albertson TE, Southard J, Owen KP, Mills LD, Diercks DB. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure. Clin Toxicol (Phila) 2013; 51:540-544.